Claire M Lanier1, Ryan Hughes1, Tamjeed Ahmed2, Michael LeCompte1, Adrianna H Masters1, William J Petty2, Jimmy Ruiz2,3, Pierre Triozzi2, Jing Su4, Stacy O'Neill5, Kuonosuke Watabe6, Christina K Cramer1, Adrian W Laxton7, Stephen B Tatter7, Ge Wang8, Christopher Whitlow4, Michael D Chan1. 1. Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC. 2. Department of Medicine (Hematology & Oncology), Wake Forest School of Medicine, Winston-Salem, NC. 3. W.G. (Bill) Hefner Veteran Administration Medical Center, Cancer Center, Salisbury, NC. 4. Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC. 5. Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC. 6. Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC. 7. Department of Neurosurgery, Wake Forest School of Medicine, Winston-Salem, NC. 8. Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, NY.
Abstract
BACKGROUND: The effect of immunotherapy on brain metastasis patients remains incompletely understood. Our goal was to evaluate its effect on survival, neurologic death, and patterns of failure after stereotactic radiosurgery (SRS) without prior whole-brain radiation therapy (WBRT) in patients with lung and melanoma primaries metastatic to the brain. METHODS: We performed a retrospective analysis of 271 consecutive lung or melanoma patients treated with upfront SRS for brain metastases between 2013 and 2018. Of these patients, 101 (37%) received immunotherapy and 170 (63%) did not. Forty-three percent were treated with nivolumab. Thirty-seven percent were treated with pembrolizumab. Fifteen percent were treated with ipilimumab. One percent were treated with a combination of nivolumab and ipilimumab. One percent were treated with atezolizumab. Three percent were treated with another immunotherapy regimen. Survival was estimated by the Kaplan-Meier method and cumulative incidences of neurologic death, and local and distant brain failure were estimated using death as a competing risk. RESULTS: The median overall survival (OS) of patients treated with immunotherapy vs without was 15.9 (95% CI: 13.3 to 24.8) vs 6.1 (95% CI: 5.1 to 8.8) months (P < .01). The 1-year cumulative incidence of neurologic death was 9% in patients treated with immunotherapy vs 23% in those treated without (P = .01), while nonneurologic death was not significantly different (29% vs 41%, P = .51). Median brain metastasis velocity (BMV) did not differ between groups, and rates of salvage SRS and WBRT were similar. CONCLUSIONS: The use of immunotherapy in patients with lung cancer or melanoma metastatic to the brain treated with SRS is associated with improved OS and decreased incidence of neurologic death.
BACKGROUND: The effect of immunotherapy on brain metastasis patients remains incompletely understood. Our goal was to evaluate its effect on survival, neurologic death, and patterns of failure after stereotactic radiosurgery (SRS) without prior whole-brain radiation therapy (WBRT) in patients with lung and melanoma primaries metastatic to the brain. METHODS: We performed a retrospective analysis of 271 consecutive lung or melanoma patients treated with upfront SRS for brain metastases between 2013 and 2018. Of these patients, 101 (37%) received immunotherapy and 170 (63%) did not. Forty-three percent were treated with nivolumab. Thirty-seven percent were treated with pembrolizumab. Fifteen percent were treated with ipilimumab. One percent were treated with a combination of nivolumab and ipilimumab. One percent were treated with atezolizumab. Three percent were treated with another immunotherapy regimen. Survival was estimated by the Kaplan-Meier method and cumulative incidences of neurologic death, and local and distant brain failure were estimated using death as a competing risk. RESULTS: The median overall survival (OS) of patients treated with immunotherapy vs without was 15.9 (95% CI: 13.3 to 24.8) vs 6.1 (95% CI: 5.1 to 8.8) months (P < .01). The 1-year cumulative incidence of neurologic death was 9% in patients treated with immunotherapy vs 23% in those treated without (P = .01), while nonneurologic death was not significantly different (29% vs 41%, P = .51). Median brain metastasis velocity (BMV) did not differ between groups, and rates of salvage SRS and WBRT were similar. CONCLUSIONS: The use of immunotherapy in patients with lung cancer or melanoma metastatic to the brain treated with SRS is associated with improved OS and decreased incidence of neurologic death.
Authors: E Shaw; C Scott; L Souhami; R Dinapoli; R Kline; J Loeffler; N Farnan Journal: Int J Radiat Oncol Biol Phys Date: 2000-05-01 Impact factor: 7.038
Authors: Sunit Harris; Michael D Chan; James F Lovato; Thomas L Ellis; Stephen B Tatter; J Daniel Bourland; Michael T Munley; Allan F deGuzman; Edward G Shaw; James J Urbanic; Kevin P McMullen Journal: Int J Radiat Oncol Biol Phys Date: 2012-02-17 Impact factor: 7.038
Authors: James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok Journal: N Engl J Med Date: 2015-05-31 Impact factor: 91.245
Authors: Jeffrey S Weber; Sandra P D'Angelo; David Minor; F Stephen Hodi; Ralf Gutzmer; Bart Neyns; Christoph Hoeller; Nikhil I Khushalani; Wilson H Miller; Christopher D Lao; Gerald P Linette; Luc Thomas; Paul Lorigan; Kenneth F Grossmann; Jessica C Hassel; Michele Maio; Mario Sznol; Paolo A Ascierto; Peter Mohr; Bartosz Chmielowski; Alan Bryce; Inge M Svane; Jean-Jacques Grob; Angela M Krackhardt; Christine Horak; Alexandre Lambert; Arvin S Yang; James Larkin Journal: Lancet Oncol Date: 2015-03-18 Impact factor: 41.316
Authors: Tamara Z Vern-Gross; Julia A Lawrence; L Douglas Case; Kevin P McMullen; J Daniel Bourland; Linda J Metheny-Barlow; Thomas L Ellis; Stephen B Tatter; Edward G Shaw; James J Urbanic; Michael D Chan Journal: J Neurooncol Date: 2012-09-24 Impact factor: 4.130
Authors: John T Lucas; Hentry G Colmer; Lance White; Nora Fitzgerald; Scott Isom; John D Bourland; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-23 Impact factor: 7.038
Authors: Andrew J Huang; Karen E Huang; Brandi R Page; Diandra N Ayala-Peacock; John T Lucas; Glenn J Lesser; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: J Neurooncol Date: 2014-07-22 Impact factor: 4.130
Authors: Adam G Johnson; Jimmy Ruiz; Ryan Hughes; Brandi R Page; Scott Isom; John T Lucas; Emory R McTyre; Kristin W Houseknecht; Diandra N Ayala-Peacock; Daniel J Bourland; William H Hinson; Adrian W Laxton; Stephen B Tatter; Waldemar Debinski; Kounosuke Watabe; Michael D Chan Journal: Oncotarget Date: 2015-08-07
Authors: Matthew T Neal; Michael D Chan; John T Lucas; Amritraj Loganathan; Christine Dillingham; Edward Pan; John H Stewart; J Daniel Bourland; Edward G Shaw; Stephen B Tatter; Thomas L Ellis Journal: World Neurosurg Date: 2013-02-10 Impact factor: 2.104
Authors: Richard J White; Stephen Abel; Zachary D Horne; Jonathan Lee; Howard Edington; Larisa Greenberg; Hashem Younes; Christie Hilton; Rodney E Wegner Journal: J Neurooncol Date: 2020-06-15 Impact factor: 4.130
Authors: Mohammed Abdulhaleem; Hannah Johnston; Ralph D'Agostino; Claire Lanier; Michael LeCompte; Christina K Cramer; Jimmy Ruiz; Thomas Lycan; Hui-Wen Lo; Kuonosuke Watabe; Stacey O'Neill; Christopher Whitlow; Jaclyn J White; Stephen B Tatter; Adrian W Laxton; Jing Su; Michael D Chan Journal: J Neurooncol Date: 2022-02-15 Impact factor: 4.130
Authors: Michael C LeCompte; Ryan T Hughes; Michael Farris; Adrianna Masters; Michael H Soike; Claire Lanier; Chase Glenn; Christina K Cramer; Kounosuke Watabe; Jing Su; Jimmy Ruiz; Christopher T Whitlow; Ge Wang; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: J Neurooncol Date: 2020-01-01 Impact factor: 4.130
Authors: Ammoren E Dohm; Tanner M Nickles; Caroline E Miller; Haley J Bowers; Michael I Miga; Albert Attia; Michael D Chan; Jared A Weis Journal: Med Phys Date: 2021-06-16 Impact factor: 4.506